3,266
Views
111
CrossRef citations to date
0
Altmetric
Editorial

Tanshinone II-A: new perspectives for old remedies

, PhD & , MD, PhD
Pages 149-153 | Published online: 12 Dec 2012
 

Abstract

Tanshinone II-A (TSN) is the most abundant diterpene quinone isolated from Danshen (Salvia miltiorrhiza), which has been used in treating cardiovascular diseases for more than 2000 years in China. Interest in its versatile protective effects in cardiovascular, metabolic, neurodegenerative diseases, and cancers has been growing over the last decade. TSN is a multi-target drug, whose molecular targets include transcription factors, scavenger receptors, ion channels, kinases, pro- and anti-apoptotic proteins, growth factors, inflammatory mediators, microRNA, and others. More recently, enhanced or synergistic effects can be observed when TSN is used in combination therapy with cardioprotective and anti-cancer drugs. These combination therapy regimens may open new therapeutic avenues for the treatment of various kinds of human diseases.

Acknowledgments

The authors gratefully acknowledge the contribution of investigators dedicated to the isolation, preparation, and pharmacological characterization of tanshinones and their derivatives, and we apologize to those investigators whose work we could not cite due to reference limit. This work was supported by research grants from the National Natural Science Foundation of China (No. 81072641, No. 81273499), the National Science and Technology Major Project of China “Key New Drug Creation and Manufacturing Program” (No. 2011ZX09401-307) Team Item of Natural Science Foundation of Guangdong Province (No. S2011030003190), Major Project of Guangdong Province (No. 2008A030201013, No. 2012A080201007), Major Project of Department of Education of Guangdong Province (No.CXZD1006), and ‘‘New Investigator Award” from Ministry of Education of China.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.